Literature DB >> 9626376

Community pharmacist interventions in a capitated pharmacy benefit contract.

K K Knapp1, H Katzman, J S Hambright, D H Albrant.   

Abstract

Documented interventions associated with processing prescriptions in a managed care environment were analyzed, and a bench-mark for interventions was proposed. A retrospective analysis of documented interventions by 31 pharmacies contracted by a managed care organization to serve 22,000 Medi-Cal patients was undertaken. An intervention consisted of identifying any problem related to a prescription, taking action, and recording the problem, action, and outcome on a form. Problems were categorized as drug selection issues, clinical issues, errors in prescription writing, and patient education issues. A similar process was followed for describing actions and outcomes. The data were used as an indicator of prescription-related problems in contemporary pharmacies in a managed care environment; data from another study were used as an indicator of "ideal" pharmacist performance in detecting and resolving problems. The estimated intervention rate when pharmacists meeting ideal performance expectations worked in a managed care environment was set as a benchmark. The economic impact of drug selection interventions was determined as well. Data were retrieved and compiled from 595 (93.4%) of 637 interventions performed in 1995, when 93,483 contract-related prescriptions were processed by the 31 pharmacies. Fifty percent of problems related to drug selection issues. The most frequent action was contacting the presciber (56.1%). The overall intervention rate was 0.7% (range, 0-4.1%). It was estimated that 4% of prescriptions would require an intervention; two pharmacies met this level. Interventions resulting in prescription change realized an average decrease in cost of 65.8%. Community pharmacies under contract with a managed care organization intervened on 0.7% of prescriptions, but the rate of intervention across pharmacies was inconsistent, ranging from 0% to 4.1%; a benchmark of 4% would be reasonable.

Entities:  

Mesh:

Year:  1998        PMID: 9626376     DOI: 10.1093/ajhp/55.11.1141

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  8 in total

1.  Frequency and trends of interventions of prescriptions in Flemish community pharmacies.

Authors:  Lies Leemans; Luc Veroeveren; Jef Bulens; Christiane Hendrickx; Williame Keyenberg; Frie Niesten; Jules Vandeberg; Jacques Van Hoof; Gert Laekeman
Journal:  Pharm World Sci       Date:  2003-04

2.  Pharmaceutical interventions on prescription problems in a Danish pharmacy setting.

Authors:  Anton Pottegård; Jesper Hallas; Jens Søndergaard
Journal:  Int J Clin Pharm       Date:  2011-11-15

3.  Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions.

Authors:  Henk Buurma; Peter A G M De Smet; Antoine C G Egberts
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Practical evaluation of the drug-related problem management process in Swiss community pharmacies.

Authors:  Jean-Marc Krähenbühl; Bertha Kremer; Bertrand Guignard; Olivier Bugnon
Journal:  Pharm World Sci       Date:  2008-04-06

5.  Classification of drug-related problems with new prescriptions using a modified PCNE classification system.

Authors:  Patrick M Eichenberger; Markus L Lampert; Irene Vogel Kahmann; J W Foppe van Mil; Kurt E Hersberger
Journal:  Pharm World Sci       Date:  2010-03-13

6.  An evaluation of the knowledge and perceptions of pharmacy students on pharmacovigilance activities in Nigeria.

Authors:  Kanayo P Osemene; Margaret O Afolabi
Journal:  BMC Res Notes       Date:  2017-07-12

7.  The Practice Guidelines for Multidose Drug Dispensing Need Revision-An Investigation of Prescription Problems and Interventions.

Authors:  Anette Vik Josendal; Trine S Bergmo; Anne Gerd Granas
Journal:  Pharmacy (Basel)       Date:  2021-01-06

8.  Assessment of ePrescription quality: an observational study at three mail-order pharmacies.

Authors:  Bengt Astrand; Emelie Montelius; Göran Petersson; Anders Ekedahl
Journal:  BMC Med Inform Decis Mak       Date:  2009-01-26       Impact factor: 2.796

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.